Show simple item record

dc.contributor.authorTrento, Alfonsina 
dc.contributor.authorBerenguer, Juan
dc.contributor.authorFernandez-Rodriguez, Amanda 
dc.contributor.authorPineda-Tenor, Daniel 
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorGarcia-Alvarez, Monica 
dc.contributor.authorMiralles, Pilar
dc.contributor.authorAldámiz-Echevarria, Teresa
dc.contributor.authorLópez, Juan Carlos
dc.contributor.authorMicheloud, Dariela
dc.contributor.authorResino, Salvador
dc.identifier.citationJ Transl Med. 2014; 12: 235
dc.description.abstractBackground: Peroxisome proliferator-activated receptor gamma-2 gene (PPARγ2) rs1801282 (Pro12Ala) polymorphism has been associated with lower risk of metabolic disturbance and atherosclerosis. The aim of this study was to analyze the association between the Pro12Ala polymorphism and cardiometabolic risk factors in human immunodeficiency virus (HIV)/Hepatitis C virus (HCV)-coinfected patients. Methods: We carried out a cross-sectional study on 257 HIV/HCV coinfected patients. PPARγ2 polymorphism was genotyped by GoldenGate® assay. The main outcome measures were: i) serum lipids (cholesterol, triglycerides, high-density lipoprotein (HDL-C), low-density lipoprotein (LDL-C), LDL-C/HDL-C, and atherogenic index (AI)); ii) homeostatic model assessment (HOMA-IR) values; iii) serum adipokines (leptin, adiponectin, resistin, plasminogen activator inhibitor-1(PAI-1), hepatic growth factor (HGF), and nerve growth factor (NGF)). Generalized Linear Models (GLM) with gamma distribution (log-link) were used to investigate the association between PPARγ2 polymorphism and continuous outcome variables. This test gives the differences between groups and the arithmetic mean ratio (AMR) in continuous outcome variables between groups. Results: The rs1801282 CG/GG genotype was associated with low values of cholesterol (adjusted arithmetic mean ratio (aAMR) = 0.87 (95% of confidence interval (95% CI) = 0.79; 0.96); p = 0.004) and LDL-C (aAMR = 0.79 (95% CI = 0.68; 0.93); p = 0.004). Furthermore, rs1801282 CG/GG was associated with low values of HOMA-IR (aAMR = 0.69 (95% CI = 0.49; 0.98); p = 0.038) among patients with significant liver fibrosis (F ≥ 2). Moreover, rs1801282 CG/GG was also associated with low serum values of hepatic growth factor (HGF) (aAMR = 0.61 (95% CI = 0.39; 0.94); p = 0.028), and nerve growth factor (NGF) (aAMR = 0.47 (95% CI = 0.26; 0.84); p = 0.010). The serum levels of leptin, adiponectin, resistin, and PAI-1 did not show significant differences. Conclusions: The presence of PPARγ2 rs1801282 G allele (Ala variant) was associated with a protective cardiometabolic risk profile versus CC genotype in HIV/HCV-coinfected patients. Thus, PPARγ2 rs1801282 polymorphism may play a significant role in the development of metabolic disorders in HIV/HCV coinfected patients, and might have an influence on the cardiovascular risk.
dc.description.sponsorshipFunding/Support: This work has been supported by grants given by Fondo de Investigación de Sanidad en España (FIS) [Spanish Health Founds for Research] [grant numbers PI08/0738, PI11/00245; PI08/0928, and PI11/01556], and “Fundación para la Investigación y la Prevención del Sida en España” (FIPSE) [grant number 361020/10]. This work has been (partially) funded by the RD12/0017/0024 and RD12/0017/0004 projects as part of the Plan Nacional R + D + I and cofinanced by ISCIII- Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER). JB is an investigator from the Programa de Intensificación de la Actividad Investigadora en el Sistema Nacional de Salud (I3SNS), Refs INT10/009 and INT12/154. PGB, AFR, DPT, MAJS and MGA are supported by “Instituto de Salud Carlos III” [grant numbers FI12/00036, UIPY-1377/08, CM12/00043, CD13/00013 and CD12/00442, respectively].
dc.publisherBioMed Central (BMC) 
dc.subjectHIV/HCV coinfection
dc.subjectSerum lipids
dc.subjectInsulin resistance
dc.subjectSingle nucleotide polymorphism
dc.titlePPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study
dc.typejournal article
dc.rights.licenseAtribución 4.0 Internacional*
dc.contributor.funderFundación para la Investigación y la Prevención del Sida en España 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderInstituto de Salud Carlos III 
dc.identifier.journalJournal of Translational Medicine
dc.repisalud.centroISCIII::Centro Nacional de Microbiología::Área de Patología Molecular::Unidad de Infección viral e Inmunidad
dc.rights.accessRightsopen accesses_ES

Files in this item

Acceso Abierto

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional